These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

111 related items for PubMed ID: 10423250

  • 21. Stabilization of an isolated helical capping box in solution by hydrophobic interactions: evidence from the NMR study of bioactive peptides from the C-terminus of human C5a anaphylatoxin.
    Ni F, Carpenter KA, Ripoll DR, Sanderson SD, Hugli TE.
    Biopolymers; 1996 Jan; 38(1):31-41. PubMed ID: 8679942
    [Abstract] [Full Text] [Related]

  • 22. Biologically active conformer of the effector region of human C5a and modulatory effects of N-terminal receptor binding determinants on activity.
    Finch AM, Vogen SM, Sherman SA, Kirnarsky L, Taylor SM, Sanderson SD.
    J Med Chem; 1997 Mar 14; 40(6):877-84. PubMed ID: 9083476
    [Abstract] [Full Text] [Related]

  • 23. A detailed analysis of the C5a anaphylatoxin effector domain: selection of C5a phage libraries on differentiated U937 cells.
    Hennecke M, Otto A, Baensch M, Kola A, Bautsch W, Klos A, Köhl J.
    Eur J Biochem; 1998 Feb 15; 252(1):36-44. PubMed ID: 9523709
    [Abstract] [Full Text] [Related]

  • 24. Multiple regions of G alpha 16 contribute to the specificity of activation by the C5a receptor.
    Lee CH, Katz A, Simon MI.
    Mol Pharmacol; 1995 Feb 15; 47(2):218-23. PubMed ID: 7870028
    [Abstract] [Full Text] [Related]

  • 25. Requirements for C5a receptor-mediated IL-4 and IL-13 production and leukotriene C4 generation in human basophils.
    Eglite S, Plüss K, Dahinden CA.
    J Immunol; 2000 Aug 15; 165(4):2183-9. PubMed ID: 10925305
    [Abstract] [Full Text] [Related]

  • 26. The orphan receptor C5L2 has high affinity binding sites for complement fragments C5a and C5a des-Arg(74).
    Cain SA, Monk PN.
    J Biol Chem; 2002 Mar 01; 277(9):7165-9. PubMed ID: 11773063
    [Abstract] [Full Text] [Related]

  • 27. Chemotactic responses of human peripheral blood monocytes to the complement-derived peptides C5a and C5a des Arg.
    Marder SR, Chenoweth DE, Goldstein IM, Perez HD.
    J Immunol; 1985 May 01; 134(5):3325-31. PubMed ID: 3884709
    [Abstract] [Full Text] [Related]

  • 28. Epitope mapping of a C5a neutralizing mAb using a combined approach of phage display, synthetic peptides and site-directed mutagenesis.
    Kola A, Baensch M, Bautsch W, Hennecke M, Klos A, Casaretto M, Köhl J.
    Immunotechnology; 1996 Jun 01; 2(2):115-26. PubMed ID: 9373320
    [Abstract] [Full Text] [Related]

  • 29. Pivotal Advance: Interconversion between pure chemotactic ligands and chemoattractant/secretagogue ligands of neutrophil C5a receptor by a single amino acid substitution.
    Jia N, Semba U, Nishiura H, Kuniyasu A, Nsiama TK, Nishino N, Yamamoto T.
    J Leukoc Biol; 2010 Jun 01; 87(6):965-75. PubMed ID: 20089669
    [Abstract] [Full Text] [Related]

  • 30. Stabilization of C5a receptor--G-protein interactions through ligand binding.
    Wennogle LP, Conder L, Winter C, Braunwalder A, Vlattas S, Kramer R, Cioffi C, Hu SI.
    J Cell Biochem; 1994 Jul 01; 55(3):380-8. PubMed ID: 7962171
    [Abstract] [Full Text] [Related]

  • 31. Altered expression of CD88 and associated impairment of complement 5a-induced neutrophil responses in human immunodeficiency virus type 1-infected patients with and without pulmonary tuberculosis.
    Meddows-Taylor S, Pendle S, Tiemessen CT.
    J Infect Dis; 2001 Feb 15; 183(4):662-5. PubMed ID: 11170995
    [Abstract] [Full Text] [Related]

  • 32. Agonist and antagonist dual effect of the cross-linked S19 ribosomal protein dimer in the C5a receptor-mediated respiratory burst reaction of phagocytic leukocytes.
    Revollo I, Nishiura H, Shibuya Y, Oda Y, Nishino N, Yamamoto T.
    Inflamm Res; 2005 Feb 15; 54(2):82-90. PubMed ID: 15750715
    [Abstract] [Full Text] [Related]

  • 33. Switch moiety in agonist/antagonist dual effect of S19 ribosomal protein dimer on leukocyte chemotactic C5a receptor.
    Shrestha A, Shiokawa M, Nishimura T, Nishiura H, Tanaka Y, Nishino N, Shibuya Y, Yamamoto T.
    Am J Pathol; 2003 Apr 15; 162(4):1381-8. PubMed ID: 12651630
    [Abstract] [Full Text] [Related]

  • 34. Structure and function of human C5a anaphylatoxin. Selective modification of tyrosine 23 alters biological activity but not antigenicity.
    Johnson RJ, Chenoweth DE.
    J Biol Chem; 1985 Aug 25; 260(18):10339-45. PubMed ID: 2410424
    [Abstract] [Full Text] [Related]

  • 35. Comparative agonist/antagonist responses in mutant human C5a receptors define the ligand binding site.
    Higginbottom A, Cain SA, Woodruff TM, Proctor LM, Madala PK, Tyndall JD, Taylor SM, Fairlie DP, Monk PN.
    J Biol Chem; 2005 May 06; 280(18):17831-40. PubMed ID: 15661745
    [Abstract] [Full Text] [Related]

  • 36. Identification of receptor-binding sites of monocyte chemotactic S19 ribosomal protein dimer.
    Shibuya Y, Shiokawa M, Nishiura H, Nishimura T, Nishino N, Okabe H, Takagi K, Yamamoto T.
    Am J Pathol; 2001 Dec 06; 159(6):2293-301. PubMed ID: 11733378
    [Abstract] [Full Text] [Related]

  • 37. Identification of classical anaphylatoxin as the des-Arg form of the C5a molecule: evidence of a modulator role for the oligosaccharide unit in human des-Arg74-C5a.
    Gerard C, Hugli TE.
    Proc Natl Acad Sci U S A; 1981 Mar 06; 78(3):1833-7. PubMed ID: 6940191
    [Abstract] [Full Text] [Related]

  • 38. Identification of an antigenic epitope and receptor binding domain of human C5a.
    Johnson RJ, Tamerius JD, Chenoweth DE.
    J Immunol; 1987 Jun 01; 138(11):3856-62. PubMed ID: 2438329
    [Abstract] [Full Text] [Related]

  • 39. Antisense homology boxes in C5a receptor and C5a anaphylatoxin: a new method for identification of potentially active peptides.
    Baranyi L, Campbell W, Okada H.
    J Immunol; 1996 Nov 15; 157(10):4591-601. PubMed ID: 8906838
    [Abstract] [Full Text] [Related]

  • 40. Response-selective C5a agonists: differential effects on neutropenia and hypotension in the rat.
    Short AJ, Paczkowski NJ, Vogen SM, Sanderson SD, Taylor SM.
    Br J Pharmacol; 1999 Oct 15; 128(3):511-4. PubMed ID: 10516626
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 6.